{"id":917077,"date":"2025-12-07T16:03:03","date_gmt":"2025-12-07T21:03:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/"},"modified":"2025-12-07T16:03:03","modified_gmt":"2025-12-07T21:03:03","slug":"wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/","title":{"rendered":"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Dec.  07, 2025  (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave\u2019s proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET.<\/p>\n<p>A webcast of the conference call can be accessed by visiting \u201cInvestor Events\u201d on the investor relations section of the\u00a0Wave Life Sciences\u00a0website:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PNyTHchsVMjQxvpHK5pR4SMb0izzvxSx8HZsC41lE__vToQu6tpSCqdljr7IcddBTv8L5Pu4PAjNKlYQNuHKCv2Ld98BUjaCDq_gF28dSIA4fa6MmIDQ_ITXay_bk_m_pxTEtHX2Emt2RTSnQWwwi6k_Rpxit7dqLqD2MdM8E_A86cN2A37VTvJoeRz2XrJqnO2Ze2-5HunhPVibPB_CX432lEi7590oWNim3nHEC1eTe9ZHeWD_qjOT4mVlsrgRmjfdtKPqworQ9ceoxTZsqU4aOw6YLRLDmUeHTy0oSWNMBEw21pLJuFWsbNHc45BD7ccZAisKH5UCKYsmEK7SZ49olXDHybxaPDzP4dk3PgBVNT5qCRpub7SIdv9VU8Ey1R--lfLbON_kDIYdX-sp5xW_YV5G_XblLS1pXRDAcsk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.wavelifesciences.com\/events-publications\/events<\/a>. Following the live event, an archived version of the webcast will be available on the\u00a0Wave Life Sciences\u00a0website.<\/p>\n<p>\n        <strong>About WVE-007<\/strong><br \/>\n        <br \/>WVE-007 is an investigational GalNAc-siRNA that utilizes Wave\u2019s best-in-class proprietary oligonucleotide chemistry and the company\u2019s Stereopure interfering Nucleic Acid (SpiNA) next generation siRNA design. WVE-007 is designed to silence INHBE mRNA, an obesity target with strong evidence from human genetics. Individuals who have a protective loss-of-function variant in one copy of the INHBE gene have a healthier body composition and cardiometabolic profile, including less visceral fat and lower risk of type 2 diabetes or cardiovascular disease. In preclinical models, INHBE GalNAc-siRNA led to adipocyte shrinkage, fewer pro-inflammatory macrophages, less fibrosis, and improved insulin sensitivity in visceral adipose tissue, supporting potential for metabolic improvement. As an add-on to semaglutide, Wave\u2019s GalNAc-siRNA doubled weight loss in mice and prevented weight regain upon cessation of semaglutide.<\/p>\n<p>\n        <strong>About the INLIGHT Clinical Trial<\/strong><br \/>\n        <br \/>INLIGHT is an ongoing, first-in-human clinical trial (3:1 active: placebo) evaluating WVE-007 in adults living with overweight or obesity and assesses safety, tolerability, pharmacokinetics, Activin E, body weight and composition, and biomarkers of metabolic health. INLIGHT is currently ongoing at multiple trial sites, including in the US.<\/p>\n<p>\n        <strong>About\u00a0Wave Life Sciences<\/strong><br \/>\n        <br \/>Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave\u2019s RNA medicines platform, PRISM<sup>\u00ae<\/sup>, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave\u2019s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington\u2019s disease, as well as several preclinical programs utilizing the company\u2019s broad RNA therapeutics toolkit. Driven by the calling to \u201cReimagine Possible,\u201d Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave\u2019s science, pipeline and people, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8MEUTaYzl1ujY4BfqVdCGLeB9EBCOHCII0qopmsK42kHuT6D5iJrWajPdQto0GKOtRlOSZCcRDa3hVuzx7qrek-NFgno_5ny5uf4RlBhEnukBad3zDEv2SUlR9DPOyl6\" rel=\"nofollow\" target=\"_blank\">www.wavelifesciences.com<\/a> and follow Wave on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VbsQUYR5oZfoQeRjNZ7U9nAmiX7Pallv7BELshLmuaemvMLU0_FBCPmB954G3vVc0elvscXmXJMEXb5ku2hUXA==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vbWLjaxrQXf7rk-Ls8hDH35Bp-ZmEebMAmpd2af7yXvykmQxzlcWIz_XkNstXxpUESsyutnYo2p3lEXmE-Kkgdr0I2SIwMjPDhePsn_-uwQPF6fb0PccGgKYZeILcRew\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Kate Rausch<br \/>VP, Corporate Affairs and Investor Relations<br \/>+1 617-949-4827<\/p>\n<p><strong>Investors:<\/strong><br \/>James Salierno<br \/>Director, Investor Relations<br \/>+1 617-949-4043 <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FgdggPoE4RUISJKWFqYCTuLxuER6ZZFSOv7AHE99lQHMwqUbI2TsSqSF9PBICN_pGabbbmnu_JSkcFEaqsFLTQBPXcni9H4Xy4AlkjzJY3ABARAnpeD5v_f_AWTc2WQQb_3vpf5nQJSY4jE426Hthw==\" rel=\"nofollow\" target=\"_blank\">InvestorRelations@wavelifesci.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong>:<br \/>Katie Sullivan<br \/>Senior Director, Corporate Communications<br \/>+1 617-949-2936<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5s8HoA1zN5SzlSlZpI6J1kO9augaXIHVUYf7kzO78mJp-X92K2RSaIGQFuBlm1XWnCluHb0qXoXFfTaK5GLVU9Z0vFjPc6bjWbjlHdvh38RdaTNF5ogSU3iunxS7Q7f-\" rel=\"nofollow\" target=\"_blank\">MediaRelations@wavelifesci.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2RlYTM0ODQtMGFmNy00OWI4LWI0NjAtMDVhZDYxNmIyNmUzLTEwMzE4NjAtMjAyNS0xMi0wNy1lbg==\/tiny\/Wave-Life-Sciences-USA-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave\u2019s proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. A webcast of the conference call can be accessed by visiting \u201cInvestor Events\u201d on the investor relations section of the\u00a0Wave Life Sciences\u00a0website:\u00a0https:\/\/ir.wavelifesciences.com\/events-publications\/events. Following the live event, an archived version of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917077","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave\u2019s proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. A webcast of the conference call can be accessed by visiting \u201cInvestor Events\u201d on the investor relations section of the\u00a0Wave Life Sciences\u00a0website:\u00a0https:\/\/ir.wavelifesciences.com\/events-publications\/events. Following the live event, an archived version of &hellip; Continue reading &quot;Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-07T21:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025\",\"datePublished\":\"2025-12-07T21:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/\"},\"wordCount\":536,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/\",\"name\":\"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=\",\"datePublished\":\"2025-12-07T21:03:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/","og_locale":"en_US","og_type":"article","og_title":"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) &#8212; Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will announce interim data from the ongoing Phase 1 INLIGHT clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA using Wave\u2019s proprietary SpiNA design, for the treatment of obesity on Monday, December 8, 2025. A press release announcing the interim data will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. A webcast of the conference call can be accessed by visiting \u201cInvestor Events\u201d on the investor relations section of the\u00a0Wave Life Sciences\u00a0website:\u00a0https:\/\/ir.wavelifesciences.com\/events-publications\/events. Following the live event, an archived version of &hellip; Continue reading \"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-07T21:03:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025","datePublished":"2025-12-07T21:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/"},"wordCount":536,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/","name":"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=","datePublished":"2025-12-07T21:03:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5ODE5NCM3MzEwMTg4IzIwMjAyODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wave-life-sciences-to-announce-interim-data-from-the-phase-1-inlight-trial-of-wve-007-inhbe-for-obesity-on-monday-december-8-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917077","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917077"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917077\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}